|
Asian Journal of Andrology (2012) 14, 405-408; doi:10.1038/aja.2011.149; published online 20 February 2012
Cyr61 is a potential prognostic marker for prostate cancer
Naoki Terada1, Prakash Kulkarni1,2 and Robert H Getzenberg1,2,3
1 Department of Urology, the James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
2 Department of Urology Oncology, The Johns Hopkins University School of Medicine, Baltimore, Baltimore, MD 21287, USA
3 Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Correspondence: Dr RH Getzenberg, (rgetzen1@jhmi.edu)
Received 16 September 2011; Revised 29 November 2011; Accepted 29 November 2011
Advance online publication 20 February 2012.
| Abstract |
Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling that is frequently altered in expression in several types of cancers. In prostate cancer (PCa), Cyr61 is highly expressed in organ-confined disease. Further, Cyr61 expression levels are associated with a lower risk of disease recurrence, and can be quantitatively measured in the serum. Considered together, these results indicate that Cyr61 is a potential and clinically useful tissue, as well as serum-based biomarker for differentiating lethal and non-lethal PCa.
Keywords: Cyr61; lethal prostate cancer; non-lethal prostate cancer; overdiagnosis; overtreatment; prostate cancer |
|
